Enanta Pharma (ENTA) Reports Q2 EPS of $1.49

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of $1.49, may note compare to the analyst estimate of $1.76. Revenue for the quarter came in at $57.4 million versus the consensus estimate of $63.4 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
• APi Group closes WTech Fire Group deal, raises 2026 guidance
• Rivian raises 2026 delivery outlook after Q2 results top guidance